JP2024514182A5 - - Google Patents
Info
- Publication number
- JP2024514182A5 JP2024514182A5 JP2023563061A JP2023563061A JP2024514182A5 JP 2024514182 A5 JP2024514182 A5 JP 2024514182A5 JP 2023563061 A JP2023563061 A JP 2023563061A JP 2023563061 A JP2023563061 A JP 2023563061A JP 2024514182 A5 JP2024514182 A5 JP 2024514182A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- vaccine according
- antigenic polypeptide
- encoding
- respiratory viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163174463P | 2021-04-13 | 2021-04-13 | |
| US63/174,463 | 2021-04-13 | ||
| US202163175011P | 2021-04-14 | 2021-04-14 | |
| US63/175,011 | 2021-04-14 | ||
| US202163241959P | 2021-09-08 | 2021-09-08 | |
| US63/241,959 | 2021-09-08 | ||
| US202263322121P | 2022-03-21 | 2022-03-21 | |
| US63/322,121 | 2022-03-21 | ||
| PCT/US2022/024497 WO2022221335A1 (en) | 2021-04-13 | 2022-04-12 | Respiratory virus combination vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514182A JP2024514182A (ja) | 2024-03-28 |
| JP2024514182A5 true JP2024514182A5 (https=) | 2025-04-17 |
Family
ID=81449216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563061A Pending JP2024514182A (ja) | 2021-04-13 | 2022-04-12 | 呼吸器ウイルス組み合わせワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240216500A1 (https=) |
| EP (1) | EP4322993A1 (https=) |
| JP (1) | JP2024514182A (https=) |
| AU (1) | AU2022258335A1 (https=) |
| WO (1) | WO2022221335A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| EP4274607A1 (en) | 2021-01-11 | 2023-11-15 | ModernaTX, Inc. | Seasonal rna influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN120435314A (zh) * | 2022-12-29 | 2025-08-05 | 波普瓦克斯私人有限公司 | 多靶疫苗和治疗剂 |
| TW202438672A (zh) * | 2023-01-31 | 2024-10-01 | 美商亞克圖羅斯醫療公司 | 四價流感疫苗之方法及組成物 |
| CN121419787A (zh) * | 2023-06-28 | 2026-01-27 | 赛诺菲巴斯德有限公司 | 多价流感mRNA疫苗 |
| WO2025186719A1 (en) * | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026003577A1 (en) * | 2024-06-25 | 2026-01-02 | Popvax Private Limited | Multisubunit hepacivirus vaccines and therapeutics |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| EP2848692B1 (en) * | 2004-05-21 | 2017-08-16 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for influenza virus vaccines |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| JP2010531640A (ja) | 2007-06-29 | 2010-09-30 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | 毒性化合物の分解方法 |
| SG10201408162PA (en) | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
| CA2826058C (en) * | 2011-02-04 | 2017-06-06 | Zoetis Llc | Compositions for canine respiratory disease complex |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| EP2858679B2 (en) | 2012-06-08 | 2024-06-05 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| EP3388834B1 (en) | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| CA3040337A1 (en) * | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| CA3170740A1 (en) * | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| CN112546211A (zh) * | 2020-10-23 | 2021-03-26 | 嘉晨西海(杭州)生物技术有限公司 | 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法 |
-
2022
- 2022-04-12 JP JP2023563061A patent/JP2024514182A/ja active Pending
- 2022-04-12 US US18/555,087 patent/US20240216500A1/en active Pending
- 2022-04-12 EP EP22720218.1A patent/EP4322993A1/en active Pending
- 2022-04-12 WO PCT/US2022/024497 patent/WO2022221335A1/en not_active Ceased
- 2022-04-12 AU AU2022258335A patent/AU2022258335A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514182A5 (https=) | ||
| JP2024513999A5 (https=) | ||
| US11771652B2 (en) | Lipid nanoparticles for delivering mRNA vaccines | |
| JP7817257B2 (ja) | ｍＲＮＡワクチンを送達するための脂質ナノ粒子 | |
| JP2024503698A5 (https=) | ||
| Melero et al. | The Pneumovirinae fusion (F) protein: A common target for vaccines and antivirals | |
| JP2011504486A5 (https=) | ||
| JPH11500409A (ja) | ワクチン組成物用アジュバント | |
| TW202333780A (zh) | 冠狀病毒疫苗 | |
| Fotouhi et al. | Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus | |
| JP2009539965A5 (https=) | ||
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| TW201427686A (zh) | 改良之疫苗組成物及使用方法 | |
| JP2016106093A (ja) | インフルエンザワクチンの製造方法 | |
| US11878055B1 (en) | Coronavirus vaccine | |
| JP2015500854A5 (https=) | ||
| US12208136B2 (en) | Coronavirus vaccine | |
| Chaparian et al. | A virion-based combination vaccine protects against influenza and SARS-CoV-2 disease in mice | |
| JP2024015475A (ja) | コロナウイルスワクチン | |
| JP2009514839A5 (https=) | ||
| EP4676526A2 (en) | Nucleic acid influenza vaccines and respiratory virus combination vaccines | |
| CN121038810A (zh) | 针对冠状病毒感染、流行性感冒感染和/或rsv感染的组合疫苗 | |
| CN116650633A (zh) | 冠状病毒疫苗 | |
| US20240207391A1 (en) | Engineered influenza viruses expressing sars-cov-2 antigens, vaccines and methods of making and using the same | |
| US20240366747A1 (en) | Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs |